Stephen V Liu, MD· @StephenVLiu · X·· 14 小时前评分70
正文 · 原文
#ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs 34.9m, HR 0.48. RR 81% vs 68%. Toxicities below. Very impressive. #ESMOAmbassadors
18 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Stephen V Liu, MD · x.com